n.a. (PATH)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

Latest News

NuPathe Picks Teva as Merger Partner

NuPathe Picks Teva as Merger Partner

Teva Pharmaceutical Industries won a bid to purchase Malvern, Pa.-based NuPathe with an offer that came in at only $9 million more than its M&A rival, Endo Health Solutions.

Endo Merger Agreement With NuPathe Terminated

Endo Merger Agreement With NuPathe Terminated

-- Endo congratulates NuPathe on negotiating an improved agreement with Teva and accepts termination fee

Teva Expands CNS Specialty Business With Acquisition Of NuPathe

Teva Expands CNS Specialty Business With Acquisition Of NuPathe

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that it has entered into a definitive agreement under which Teva will acquire NuPathe Inc.

Why NuPathe Inc. (PATH) Is Up Today

Why NuPathe Inc. (PATH) Is Up Today

NuPathe Inc. (PATH) rose 36% in early morning trading Wednesday after Teva Pharmaceuticals made a bid of $114 million to acquire it.

NUPATHE INVESTOR ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of NuPathe Inc. (PATH) Over The Proposed Sale Of The Company To Endo Health Solutions (ENDP)

NUPATHE INVESTOR ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of NuPathe Inc. (PATH) Over The Proposed Sale Of The Company To Endo Health Solutions (ENDP)

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of NuPathe Inc.

PATH SHAREHOLDER ALERT: The Law Firm Of Wohl & Fruchter Is Investigating The Acquisition Of NuPathe, Inc. By Endo Health Solutions Inc.

PATH SHAREHOLDER ALERT: The Law Firm Of Wohl & Fruchter Is Investigating The Acquisition Of NuPathe, Inc. By Endo Health Solutions Inc.

The law firm of Wohl & Fruchter LLP is investigating the acquisition of NuPathe, Inc.

SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of NuPathe, Inc.

SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of NuPathe, Inc.

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of NuPathe, Inc.

INVESTOR ALERT Levi & Korsinsky, LLP Announces Investigation Of NUPATHE INC. And Its Board Of Directors In Connection With The Sale Of The Company To Endo Health Solutions

INVESTOR ALERT Levi & Korsinsky, LLP Announces Investigation Of NUPATHE INC. And Its Board Of Directors In Connection With The Sale Of The Company To Endo Health Solutions

Levi & Korsinsky notifies investors of NuPathe Inc. (“NuPathe”) (Nasdaq:PATH) of possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Endo...

Law Firm Kirby McInerney LLP Investigating Potential Claims On Behalf Of NuPathe Inc. Stockholders

Law Firm Kirby McInerney LLP Investigating Potential Claims On Behalf Of NuPathe Inc. Stockholders

Kirby McInerney LLP is investigating potential claims against the Board of Directors of NuPathe Inc.

INVESTOR ALERT Levi & Korsinsky, LLP Announces Investigation Of NUPATHE INC. And Its Board Of Directors In Connection With The Sale Of The Company To Endo Health Solutions -- PATH

INVESTOR ALERT Levi & Korsinsky, LLP Announces Investigation Of NUPATHE INC. And Its Board Of Directors In Connection With The Sale Of The Company To Endo Health Solutions -- PATH

Levi & Korsinsky notifies investors of NuPathe Inc. (“NuPathe”) (Nasdaq: PATH) of possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Endo Health...

NUPATHE SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of NuPathe Inc. (PATH) Over The Proposed Sale Of The Company To Endo Health Solutions (ENDP)

NUPATHE SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of NuPathe Inc. (PATH) Over The Proposed Sale Of The Company To Endo Health Solutions (ENDP)

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of NuPathe Inc.

NuPathe Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Acquisition By Endo Health

NuPathe Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Acquisition By Endo Health

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of NuPathe Inc.

Nupathe's Failure to Launch Leads to Modest Takeover

Nupathe's Failure to Launch Leads to Modest Takeover

Endo Pharma is buying Nupathe and its migraine armband for a 24% premium.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look poised to trade higher from current levels.

Interesting PATH Put And Call Options For June 2014

Interesting PATH Put And Call Options For June 2014

Investors in NuPathe Inc saw new options begin trading this week, for the June 2014 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 222 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look poised to trade higher from current levels.

Biotech Stock Mailbag: Apricus, Avanir

Biotech Stock Mailbag: Apricus, Avanir

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

4 Health Care Stocks Under $10 to Watch

4 Health Care Stocks Under $10 to Watch

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

5 Under-$10 Stocks Primed to Trade Higher

5 Under-$10 Stocks Primed to Trade Higher

When I trade under-$10 names, I do it almost entirely based off of the charts and technical analysis.

2013 FDA Drug Approval Decision Calendar

2013 FDA Drug Approval Decision Calendar

A list of stocks with drugs expecting FDA decisions in 2013

First 90 Days of 2013 Are Live or Die For These Biotech Stocks

First 90 Days of 2013 Are Live or Die For These Biotech Stocks

Clinical trials, drug launches and FDA approval decisions fill the early 2013 biotech calendar.